KR20230092905A - NF-κB-매개 질환의 치료 - Google Patents

NF-κB-매개 질환의 치료 Download PDF

Info

Publication number
KR20230092905A
KR20230092905A KR1020237013258A KR20237013258A KR20230092905A KR 20230092905 A KR20230092905 A KR 20230092905A KR 1020237013258 A KR1020237013258 A KR 1020237013258A KR 20237013258 A KR20237013258 A KR 20237013258A KR 20230092905 A KR20230092905 A KR 20230092905A
Authority
KR
South Korea
Prior art keywords
day
human patient
muscular dystrophy
participants
age
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237013258A
Other languages
English (en)
Korean (ko)
Inventor
제시 뎀스커
에릭 호프먼
Original Assignee
레베라겐 바이오파마 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 레베라겐 바이오파마 인코포레이티드 filed Critical 레베라겐 바이오파마 인코포레이티드
Publication of KR20230092905A publication Critical patent/KR20230092905A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
KR1020237013258A 2020-09-21 2021-09-21 NF-κB-매개 질환의 치료 Pending KR20230092905A (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202063081073P 2020-09-21 2020-09-21
US63/081,073 2020-09-21
US202163195473P 2021-06-01 2021-06-01
US63/195,473 2021-06-01
US202163214908P 2021-06-25 2021-06-25
US63/214,908 2021-06-25
PCT/US2021/051274 WO2022061287A1 (en) 2020-09-21 2021-09-21 TREATMENT OF NF-κB-MEDIATED DISEASE

Publications (1)

Publication Number Publication Date
KR20230092905A true KR20230092905A (ko) 2023-06-26

Family

ID=80776432

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237013258A Pending KR20230092905A (ko) 2020-09-21 2021-09-21 NF-κB-매개 질환의 치료

Country Status (9)

Country Link
US (2) US20220184098A1 (cg-RX-API-DMAC10.html)
EP (1) EP4213855A4 (cg-RX-API-DMAC10.html)
JP (1) JP2023543439A (cg-RX-API-DMAC10.html)
KR (1) KR20230092905A (cg-RX-API-DMAC10.html)
AU (1) AU2021343534A1 (cg-RX-API-DMAC10.html)
CA (1) CA3170698A1 (cg-RX-API-DMAC10.html)
IL (1) IL301500A (cg-RX-API-DMAC10.html)
MX (1) MX2023003258A (cg-RX-API-DMAC10.html)
WO (1) WO2022061287A1 (cg-RX-API-DMAC10.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4436583A4 (en) * 2021-11-22 2025-04-02 ReveraGen BioPharma, Inc. TREATMENT OF NF-kB-MEDIATED DISEASE
WO2025199347A1 (en) * 2024-03-21 2025-09-25 Reveragen Biopharma, Inc. Treatment of glomerulonephritis

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006279325B2 (en) * 2005-08-18 2013-06-27 Accelalox, Inc. Methods for bone treatment by modulating an arachidonic acid metabolic or signaling pathway
EP2785351A4 (en) * 2011-11-29 2015-05-27 Reveragen Biopharma Inc NONTHORMONAL STEROID MODULATORS OF NF-KB FOR THE TREATMENT OF DISEASES
WO2014205045A1 (en) * 2013-06-18 2014-12-24 Downes, Michael Methods of treating muscular dystrophy
WO2017044491A1 (en) * 2015-09-08 2017-03-16 The Children's Hospital Of Philadelphia Nonselective metabotropic glutamate receptor activators for treatment of attention deficit disorder and 22q syndrome
US11382922B2 (en) * 2019-03-07 2022-07-12 Reveragen Biopharma, Inc. Aqueous oral pharmaceutical suspension compositions

Also Published As

Publication number Publication date
AU2021343534A1 (en) 2023-05-11
MX2023003258A (es) 2023-05-08
US20220184098A1 (en) 2022-06-16
EP4213855A4 (en) 2024-10-23
EP4213855A1 (en) 2023-07-26
US20240139210A1 (en) 2024-05-02
IL301500A (en) 2023-05-01
WO2022061287A1 (en) 2022-03-24
CA3170698A1 (en) 2022-03-24
JP2023543439A (ja) 2023-10-16

Similar Documents

Publication Publication Date Title
JP7312169B2 (ja) 遺伝性てんかん性障害の処置に使用するガナキソロン
JP2024097878A (ja) 結晶性19-ノルc3,3-二置換c21-n-ピラゾリルステロイド
JP7819094B2 (ja) ヒトアミノステロールent-03化合物、それを含む関連組成物、およびそれを使用する方法
US20240139210A1 (en) Treatment of nf-kb-mediated disease
US20240245711A1 (en) A 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid for the treatment of major depressive disorder
US10537566B2 (en) Combinations comprising siponimod and laquinimod for the treatment of multiple sclerosis
EP3145513B1 (en) 3-(4-((4-(morpholinomethyl-benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione for the treatment of systemic lupus erythematosus
MXPA02001772A (es) Metodo para el tratamiento de trastornos mentales.
KR20150119227A (ko) 라퀴니모드에 의한 다발성 경화증의 진행형 형태의 치료
JP2021522344A5 (cg-RX-API-DMAC10.html)
CN107567444A (zh) 用于治疗精神分裂症的包含2‑((1‑(2‑(4‑氟苯基)‑2‑氧代乙基)哌啶‑4‑基)甲基)异吲哚啉‑1‑酮的组合物
US20240299416A1 (en) TREATMENT OF NF-kB-MEDIATED DISEASE
AU2015231076B2 (en) Carboxy-cyclopropyl undecanol compounds for treatment of liver disease and other medical disorders
US20240226117A1 (en) Treatment of congenital adrenal hypoplasia
CN116507338A (zh) NF-κB介导的疾病的治疗
JP2024527992A (ja) 神経刺激性ステロイドの結晶形
US20200038414A1 (en) Methods of treating constipation using aminosterol compositions
WO2021188148A1 (en) Crystalline forms of squalamine
CN107249592A (zh) 用于治疗阿尔茨海默病的方法
CN118146176B (zh) G蛋白偶联受体gpr133/adgrd1激动剂、制备方法及其应用
JP2026501779A (ja) Hsd-1介在性障害を治療するための方法及び組成物
CN117098554A (zh) 用于治疗重度抑郁障碍的19-去甲c3,3-二取代c21-n-吡唑基类固醇
EA052165B1 (ru) Ганаксолон для использования в лечении наследственных эпилептических заболеваний
EP4430056A1 (en) 3.beta.-hydroxy, 3.alpha.-ethyl steroids for modulation of the alpha-3 subtype of the gaba-a receptor
Krysiak et al. Coexistence of Glucocorticoid Resistance and Pseudohypoparathyroidism.

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20230419

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20240919

Comment text: Request for Examination of Application